Omnicell (NASDAQ:OMCL) Cut to “Strong Sell” at Zacks Research

Zacks Research downgraded shares of Omnicell (NASDAQ:OMCL) from a hold rating to a strong sell rating in a report released on Monday morning,Zacks.com reports.

Other equities analysts have also issued research reports about the company. KeyCorp upgraded Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target on the stock in a research note on Wednesday, January 7th. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price target for the company in a report on Wednesday, February 4th. Weiss Ratings raised shares of Omnicell from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday. Wells Fargo & Company boosted their price objective on shares of Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $49.00 target price (down previously from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Omnicell presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.50.

Omnicell Price Performance

OMCL stock opened at $37.82 on Monday. The stock has a market cap of $1.70 billion, a PE ratio of 945.74, a P/E/G ratio of 1.29 and a beta of 0.78. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.00. The company has a 50-day moving average price of $46.19 and a 200 day moving average price of $37.25. The company has a current ratio of 1.43, a quick ratio of 1.22 and a debt-to-equity ratio of 0.14.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The firm had revenue of $313.98 million during the quarter, compared to analysts’ expectations of $313.36 million. During the same period last year, the company earned $0.60 earnings per share. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Equities research analysts anticipate that Omnicell will post 1.09 earnings per share for the current year.

Insider Activity at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the transaction, the executive vice president directly owned 91,674 shares of the company’s stock, valued at $4,574,532.60. The trade was a 6.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.52% of the stock is owned by insiders.

Hedge Funds Weigh In On Omnicell

Several institutional investors and hedge funds have recently modified their holdings of the business. AQR Capital Management LLC boosted its position in Omnicell by 42.1% during the first quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock worth $627,000 after purchasing an additional 5,311 shares in the last quarter. Empowered Funds LLC lifted its holdings in Omnicell by 14.3% during the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after purchasing an additional 1,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Omnicell by 4.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after purchasing an additional 4,866 shares during the period. Jane Street Group LLC increased its stake in shares of Omnicell by 201.5% during the first quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock worth $5,722,000 after purchasing an additional 109,382 shares in the last quarter. Finally, Inspire Investing LLC increased its stake in shares of Omnicell by 33.9% during the second quarter. Inspire Investing LLC now owns 13,224 shares of the company’s stock worth $389,000 after purchasing an additional 3,346 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.